NAD+ for women: what the studies included
Reviewed 22 sourcesPublished by PepVault
Women were 41% of the people in 19 human NAD+, NMN and NR trials. The two all-women trials, the ages enrolled, and what was measured in women specifically.

- Last reviewed
- Sources
- 22
- Questions
- 7
- Compounds
- 3
The short answer
Women were 543 of the 1,335 people (41%) in the 19 human NAD+, NMN and NR trials we counted, and six trials enrolled no women. Two studied only women: NMN raised muscle insulin sensitivity 25% in postmenopausal women with prediabetes, and a 7-day NR pilot without a placebo reported fewer hot flashes. Where trials compared the sexes, NAD+ rose the same in women and men.
Evidence: Randomized trials in people for NR and NMN, most in mixed groups with results reported for women and men together; one 25-woman placebo-controlled NMN trial after menopause, and one 40-woman open-label 7-day NR pilot on menopause symptoms.

How many women were in the NAD+ studies?
We went through 19 PubMed-indexed human trials of NAD+ (the coenzyme every cell uses to make energy and repair DNA) and its two pill-form precursors, NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). It is not every small trial, but it covers each one our study pages describe and the larger NR trials. Together they enrolled 1,335 people, and 543 of them were women: 41%. The spread is wide. Two trials enrolled only women, seven more had women in the majority, and six enrolled only men.
The table lists each trial with the share of women, the ages it took in and what it was built to measure, sorted from the most women to the fewest. Ages are the trial's entry range where it gave one, otherwise the mean age of those who took part. Martens and NOPARK count the people in the final analysis, as the papers report them.
| Trial | Form | Women | Ages | What it measured |
|---|---|---|---|---|
| Yoshino 202112 | NMN | 25 of 25 (100%) | 55 to 75, past menopause | Muscle insulin sensitivity |
| Holmes 20263 | NR with pterostilbene | 40 of 40 (100%) | Over 35; means 48 and 58 | Menopause symptoms, 7 days, no placebo |
| Conze 20194 | NR | 85 of 140 (61%) | 40 to 60 | Blood NAD+ and safety |
| Katayoshi 20235 | NMN | 22 of 36 (61%) | 40 to 65 (those enrolled 40 to 59) | NAD+ metabolites, artery stiffness |
| Lin 20256 | NR with walking | 33 of 54 (61%; count worked out from the paper's per-group percentages) | 55 and over; mean 67 | Blood pressure |
| Yi 20237 | NMN | 47 of 80 (59%) | 40 to 65 | Blood NAD+, 6-minute walk |
| Fukamizu 20228 | NMN | 17 of 31 (55%) | 20 to 65 | Safety |
| Martens 20189 | NR | 13 of 24 who finished (54%) | 55 to 79 | NAD+ and tolerability |
| Christen 202610 | NR, NMN, nicotinamide | 33 of 65 (51%) | 18 to 50 | Blood NAD+ |
| NICE 202411 | NR | 42 of 90 (47%) | Mean 71 | 6-minute walk in leg-artery disease |
| NOPARK 202612 | NR | 133 of 393 analysed (34%) | 35 and over; mean 66 | Parkinson symptoms over a year |
| Yu 202613 | NAD+ drip | 45 of 180 (25%) | Means 66 and 68 | Heart pumping in heart failure |
| Liao 202114 | NMN | 8 of 48 (17%) | 27 to 50 | Aerobic capacity in runners |
| Dollerup 201815 | NR | 0 of 40 | 40 to 70 | Insulin sensitivity |
| Elhassan 201916 | NR | 0 of 12 | 70 to 80 | Muscle NAD+ |
| Igarashi 202217 | NMN | 0 of 42 | 65 and over | Blood NAD+, muscle strength |
| Akasaka 202318 | NMN | 0 of 14 | 65 and over; mean 81 | Grip and walking in diabetes |
| Irie 202019 | NMN | 0 of 10 | 40 to 60 | Single-dose safety |
| Grant 201920 | NAD+ drip | 0 of 11 | 30 to 55 | Blood NAD+ during a drip |
Two patterns stand out. The trials that enrolled women were mostly about blood NAD+, safety and fitness in healthy adults in their 40s to 60s; women under 40 appear in numbers only in Christen (18 to 50) and Fukamizu (20 to 65)810. And the trials that looked inside muscle with a biopsy or a clamp test were single-sex: Dollerup and Elhassan took only men, Yoshino only women11516. The older-age muscle-function trials, Igarashi and Akasaka, also took only men; the Igarashi team says why: they left out older women because the drop in estrogen and progesterone after menopause could affect the data1718.
Each form has a library page: /peptides/nad, /peptides/nmn and /peptides/nicotinamide-riboside. The study pages for these trials: /research/nad-yoshino-2021, /research/nad-christen-2026, /research/nad-martens-2018, /research/nad-katayoshi-2023, /research/nad-pencina-2023, /research/nmn-yi-2023, /research/nmn-liao-2021, /research/nmn-igarashi-2022, /research/nmn-akasaka-2023, /research/nmn-irie-2020 and /research/nad-yu-2026.

What did NMN do in women after menopause?
The placebo-controlled trial built around women was published in Science in 2021. Yoshino and colleagues at Washington University gave 25 postmenopausal women with prediabetes and overweight or obesity either 250 mg of NMN a day or a placebo (a look-alike capsule with nothing active in it) for 10 weeks; 13 took NMN and 12 placebo1. Entry was limited to women aged 55 to 75, at least a year past menopause, who had not used hormone therapy in the previous six months2.
The main result: muscle insulin sensitivity, measured with a clamp test that holds blood sugar steady while insulin is infused, was 25% higher after 10 weeks of NMN and unchanged on placebo. Insulin signalling inside the thigh muscle rose too, and NMN switched on genes linked to muscle remodelling. The authors compare the gain with what about 10% weight loss does1.
What did not change matters as much. Fat mass, lean mass, belly fat, liver fat, blood pressure, fasting glucose, insulin and blood fats all stayed where they were in both groups. NAD+ rose in blood cells, but NAD+ in muscle did not change; what rose in muscle were NAD+ breakdown products, which the authors read as faster NAD+ turnover1.
Why women: the team chose postmenopausal women because NMN helped female mice with diet-induced diabetes more than male mice; that sex difference was seen in mice and has not been tested head to head in people1.
Does NAD+ help with menopause symptoms?
One trial has asked, and it is a small first look. Holmes and colleagues gave 40 women over 35 a daily capsule of 250 mg NR with 50 mg of pterostilbene, a plant compound related to resveratrol, for 7 days. Thirty-two had symptoms of the menopause transition (mean age 48) and eight did not (mean age 58)3.
After a week, the women with symptoms reported less frequent and less severe bloating, hot flashes and poor sleep than at the start, and the ratio of estradiol to estrone in their urine rose. The women without symptoms reported no change3. The trial was open-label (everyone knew what they were taking) and had no placebo group (the eight women without symptoms took it too, as the comparison), which matters for symptoms the women rated themselves. Three of its authors work for the company that sells the combination3.
So the menopause question is open: one week, one product, no placebo. The treatments with labels and large trials behind them for hot flashes are in our guide on menopause, perimenopause and hormone therapy; GLP-1s and menopause covers weight at this stage.
Do women raise NAD+ as much as men?
In the two trials that tested it, yes. Christen and colleagues stratified their 65 adults by sex and age before randomizing, then put sex into the analysis: NR and NMN roughly doubled whole-blood NAD+ in 14 days, and they found no effect of sex or age on the result10. The MIB-626 trial, an NMN tablet given to 32 overweight or obese adults aged 55 to 80, also stratified by sex and found the rise in blood NMN and NAD+ was not related to sex, body mass index or age21.
Beyond that, most mixed trials report women and men together. The 12-week NMN artery trial is the exception: split by sex, artery stiffness did not differ from placebo in women or in men5. The 60-day NMN trial, 59% women, names the gap itself and calls for a larger study of whether men and women respond differently7. The walk-test and blood-pressure trials published no separate result for women6711.
What one blood NAD+ number can and cannot tell you is the subject of our guide on NAD+ blood tests, and how the three forms compare is in NAD+ vs NMN vs NR.
PepVault keeps your NMN, NR or NAD+ in your protocol with a daily reminder, so the weeks you actually took it are on the calendar when you compare a result. Set reminders in PepVault
Why do the insulin results differ between women and men?
This is the most interesting open question in the field. The NR insulin trial enrolled 40 obese, insulin-resistant men aged 40 to 70 and gave 2,000 mg a day for 12 weeks: no change in insulin sensitivity15. The NMN trial in women found a 25% gain at 250 mg a day1. Yoshino's team point to this contrast themselves1.
The two trials differ in more than sex: a different precursor, a different dose, different ages and a different starting point (prediabetes against obesity with insulin resistance). No trial we found has given the same form to women and men side by side and measured insulin with a clamp, so the data cannot say whether sex, the form or the population explains the gap. Until one does, the 25% result belongs to the group it was measured in: postmenopausal women with prediabetes on NMN.
Has NAD+ been studied in pregnancy, breastfeeding or fertility?
No human trial we found enrolled pregnant or breastfeeding women. The NR dose trial excluded them by name4, and the all-women NMN trial took only women past menopause2. That leaves no human data on NMN, NR or injected NAD+ in pregnancy, and the choice there belongs with the obstetrician or midwife who knows the pregnancy. The fertility claims come from mice: NMN restored egg quality and fertility in aged female mice22, and no trial has tested it on fertility in women.
What do people report on NAD+?
Our reports page for NAD+ (/peptides/nad/reviews) counts 22 people's own posts about NAD+ itself, mostly injected under the skin or into a muscle. It is not split by sex, and it leaves out NR and NMN, which are other molecules. Eleven of the 22 describe more energy; four describe nausea or an upset stomach, and two dizziness or low blood pressure.
Commonly reported: with injected NAD+, more energy from the first day, and a rush, nausea or a racing heart soon after it goes in; with NR and NMN capsules, little or nothing felt.
Note nausea, flushing or sleep changes in PepVault's side-effect log on the day they happen, so they sit beside that day's dose when you look back. Log it in PepVault
Sources
- Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PubMed 33888596
- ClinicalTrials.gov NCT03151239. Effect of nicotinamide mononucleotide (NMN) on cardiometabolic function: eligibility criteria. Washington University School of Medicine. clinicaltrials.gov
- Holmes HE et al. Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial. Front Aging. 2026. PubMed 42211736
- Conze D et al. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019. PubMed 31278280
- Katayoshi T et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2023. PubMed 36797393
- Lin Y et al. Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial. Geroscience. 2025. PubMed 40770531
- Yi L et al. The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023. PubMed 36482258
- Fukamizu Y et al. Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep. 2022. PubMed 36002548
- Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018. PubMed 29599478
- Christen S et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026. PubMed 41540253
- McDermott MM et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024. PubMed 38871717
- Brakedal B et al. Nicotinamide riboside for patients with early-stage Parkinson disease: the NOPARK randomized clinical trial. JAMA. 2026. PubMed 42848371
- Yu et al. Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2026. PubMed 40954388
- Liao B et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021. PubMed 34238308
- Dollerup OL et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018. PubMed 29992272
- Elhassan YS et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019. PubMed 31412242
- Igarashi M et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022. PubMed 35927255
- Akasaka H et al. Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: a prospective, placebo-controlled, double-blind study. Geriatr Gerontol Int. 2023. PubMed 36443648
- Irie J et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020. PubMed 31685720
- Grant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci. 2019. PubMed 31572171
- Pencina KM et al. MIB-626, an oral formulation of a microcrystalline unique polymorph of beta-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2023. PubMed 35182418
- Bertoldo MJ et al. NAD+ repletion rescues female fertility during reproductive aging. Cell Rep. 2020. PubMed 32049001
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.